440 related articles for article (PubMed ID: 15235125)
21. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.
Kumar-Sinha C; Ignatoski KW; Lippman ME; Ethier SP; Chinnaiyan AM
Cancer Res; 2003 Jan; 63(1):132-9. PubMed ID: 12517789
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
23. Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.
Lee JS; Sul JY; Park JB; Lee MS; Cha EY; Song IS; Kim JR; Chang ES
Phytother Res; 2013 May; 27(5):713-20. PubMed ID: 22767439
[TBL] [Abstract][Full Text] [Related]
24. Mediterranean diet, olive oil and cancer.
Colomer R; Menéndez JA
Clin Transl Oncol; 2006 Jan; 8(1):15-21. PubMed ID: 16632435
[TBL] [Abstract][Full Text] [Related]
25. HER2 overexpression and cancer targeting.
Wang SC; Hung MC
Semin Oncol; 2001 Oct; 28(5 Suppl 16):115-24. PubMed ID: 11706403
[TBL] [Abstract][Full Text] [Related]
26. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.
Wang HQ; Altomare DA; Skele KL; Poulikakos PI; Kuhajda FP; Di Cristofano A; Testa JR
Oncogene; 2005 May; 24(22):3574-82. PubMed ID: 15806173
[TBL] [Abstract][Full Text] [Related]
27. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
Li C; Cao S; Liu Z; Ye X; Chen L; Meng S
Int J Cancer; 2010 Oct; 127(7):1507-16. PubMed ID: 20063318
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells.
Menendez JA; Colomer R; Lupu R
Oncol Rep; 2004 Aug; 12(2):411-22. PubMed ID: 15254710
[TBL] [Abstract][Full Text] [Related]
29. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
[TBL] [Abstract][Full Text] [Related]
30. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells.
Ho TS; Ho YP; Wong WY; Chi-Ming Chiu L; Wong YS; Eng-Choon Ooi V
Biomed Pharmacother; 2007 Oct; 61(9):578-87. PubMed ID: 17904792
[TBL] [Abstract][Full Text] [Related]
31. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
[TBL] [Abstract][Full Text] [Related]
33. The role of overexpressed HER2 in transformation.
Neve RM; Lane HA; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S9-13. PubMed ID: 11521729
[TBL] [Abstract][Full Text] [Related]
34. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy.
Yang Z; Bagheri-Yarmand R; Balasenthil S; Hortobagyi G; Sahin AA; Barnes CJ; Kumar R
Clin Cancer Res; 2003 Aug; 9(8):3198-203. PubMed ID: 12912973
[TBL] [Abstract][Full Text] [Related]
35. tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
Menendez JA; Vazquez-Martin A; Garcia-Villalba R; Carrasco-Pancorbo A; Oliveras-Ferraros C; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2008 Dec; 8():377. PubMed ID: 19094209
[TBL] [Abstract][Full Text] [Related]
36. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.
Meden H; Kuhn W
Eur J Obstet Gynecol Reprod Biol; 1997 Feb; 71(2):173-9. PubMed ID: 9138962
[TBL] [Abstract][Full Text] [Related]
39. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
40. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
